🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#PRESS We’re joining forces with the Mary Tyler Moore Vision Initiative Mary Tyler Moore Vision Initiative to combat vision loss from diabetes, as we become the first pharmaceutical company to join their Consortium. Read the press release: bit.ly/3CmY5lb #RetinalDisease #EyeHealth

#NEWS: We presented data on our targeted cancer therapy candidate in previously treated HER2 mutated lung cancer patients at #ESMOASIA24. Learn more: bit.ly/4glbDwe

#NEWS: We are bolstering our antibody drug conjugate (ADC) portfolio with a license from Synaffix´s ADC technology to achieve our goal of transforming the lives of people with cancer. Learn more: bit.ly/426Dso7 #ResearchCollaboration #Cancer #Innovation

#NEWS: We are continuing our strong pipeline momentum with four significant new and progressing partnered projects in our focus areas of oncology and cardio-renal-metabolic diseases. Learn more: bit.ly/40mZOjL #ResearchCollaboration #Cancer #CardioMetabolic

#NEWS: The FIBRONEER™-ILD Phase III trial in people living with progressive pulmonary fibrosis (#PPF) has met its primary endpoint.  PPF is a serious condition that can cause irreversible lung damage and continued decline in lung function.  Learn more: go.boehringer.com/D74y

#NEWS: Our targeted cancer therapy candidate for previously treated patients with advanced HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) has been granted Priority Review from the U.S. FDA.   Learn more: go.boehringer.com/7CFqS

#NEWS: We are starting a Phase I/II trial of our potential first-in-class, inhaled gene therapy, which aims to improve outcomes in people with cystic fibrosis regardless of gene mutations. Learn more: bit.ly/3Qp52WD #CysticFibrosis #ResearchAndDevelopment #Innovation

#NEWS: We are looking forward to working with Salipro Biotech AB's team of scientists, to develop new medicines addressing challenging drug targets to transform patients' lives. #ResearchPartnership #DrugDiscovery #LifeForward

#Journalists: At our Annual #Press Conference on April 2, we'll discuss our performance and major milestones achieved in 2024 and provide an outlook for 2025 and beyond. Join us to get the latest news firsthand. Register now ➡️ bit.ly/4irOfhj

#NEWS: Together with Lieber Institute we are moving our joint mental health development project forward to clinical testing. The scientists are working on a novel COMT inhibitor to potentially treat cognitive impairment. #MentalHealth Learn more: bit.ly/42cqrHQ

#PRESS: In 2024, we 👉 invested EUR 6.2 billion in R&D 👉 helped more than 66 million patients 👉 further advanced our sustainability efforts 👉 kept working on breakthrough solutions that improve lives of humans & animals. Check it out ➡️ bit.ly/3FMzAzg

#NEWS: We are bolstering our antibody drug conjugate pipeline by investing CHF 27 million in a new NBE Therapeutics R&D center to transform the lives of people living with #cancer. Learn more: bit.ly/42ba7qQ #ResearchCollaboration

#NEWS: We partner with Cue Biopharma to develop a novel treatment for people living with autoimmune & inflammatory diseases. Our approach works by selectively depleting cells that drive the overshooting immune reactions 👉bit.ly/3YyJ7k3 #AutoimmuneDisease #Inflammation

#PRESS: Christian Boehringer will hand over as Chairman of the Shareholders' Committee to Hubertus von Baumbach, with effect from July 1, 2025. Shashank Deshpande will assume the role of Chairman of the Board of Managing Directors: go.boehringer.com/CBdRG

#NEWS: We are partnering with Tessellate BIO to develop first-in-class precision treatments for alternative lengthening of telomeres driven tumors, present in 10-15% of all cancers. Lean more: bit.ly/3EsYgN7 #ResearchCollaboration #Cancer

#NEWS: At #AACR2025, we presented data on our targeted cancer therapy candidate in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). Learn more about our targeted therapy candidate here: bit.ly/4jx1PkC

#NEWS: Together with Oxford Psychiatry and Cumulus Neuroscience, we are investigating new wearable technology. This will help gain insights into brain activity of people living with psychiatric disorders and develop new #PrecisionPsychiatry treatments. Learn more: bit.ly/4jsOIAN

#NEWS: We are joining forces with Tempus. By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments. Learn more: bit.ly/43owlqa #DataScience #Cancer #ResearchCollaboration

#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in NEJM. Learn more here: go.boehringer.com/1fG0l #LifeForward

#NEWS: We are presenting new data for our SIRPα inhibitors, developed in partnership with OSE Immunotherapeutics - Biotechs & immunothérapie, at #ASCO25 - another step towards our aim of addressing high unmet cancer patient needs. Learn more: bit.ly/44QhTtb #Cancer